Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7219684

COc1ccc2ccc(S(=O)(=O)NC[C@@H]3CCN(Cc4ccc5ccnc(N)c5c4)C3=O)cc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
F10 P00742 12/20 0.69
F2 P00734 5/20 0.69
PRSS1 P07477 3/20 0.54
PLG P00747 1/20 0.48
PROC P04070 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7539527 0.89 F10 (0.88) F10F2PRSS1PLGPROC
Trifluoroacetic Acid SCHEMBL7545936 0.89 F10 (0.88) F10F2PRSS1PLGPROC
Trifluoroacetic Acid SCHEMBL7219210 0.89 F10 (0.88) F10F2PRSS1PLGPROC
Trifluoroacetic Acid SCHEMBL7538032 0.87 F10 (0.52) F10F2PRSS1PLGPROC
Trifluoroacetic Acid SCHEMBL7219682 0.84 F10 (0.64) F10F2PRSS1PLGPROC
Trifluoroacetic Acid SCHEMBL7215947 0.84 F10 (0.64) F10F2PRSS1PLGPROC
Trifluoroacetic Acid SCHEMBL2329529 0.82 F10 (0.69) F10F2PRSS1PLGPROC
Trifluoroacetic Acid SCHEMBL7543675 0.82 F10 (0.47) F10F2PRSS1PLGPROC
Hydrochloric Acid SCHEMBL7544616 0.81 F10 (0.98) F10F2PRSS1PLGPROC
Hydrochloric Acid SCHEMBL7547368 0.81 F10 (0.98) F10F2PRSS1PLGPROC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602864-B1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-08-05 US claimed
US-20020013310-A1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds AVENTIS PHARMACEUTICALS PRODUCTS INC. 2002-01-31 US claimed
US-6602864-B1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-08-05 US disclosed
EP-0944386-B1 SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS AVENTIS PHARMA INC (US) 2002-09-18 EP disclosed
US-20020013310-A1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds AVENTIS PHARMACEUTICALS PRODUCTS INC. 2002-01-31 US disclosed
US-6281227-B1 INHIBITORS OF THE ACTIVITY OF FACTOR XA. AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013310-A1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds STS, ARSA, F12 F10 20/4885F2 11/4885PRSS1 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.